<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药明康德 | wechat-feeds</title><link>http://MzAwMDA5NTIxNQ.favicon.privacyhide.com/favicon.ico</link><description>全球领先的制药、生物技术以及医疗器械研发开放式能力和技术平台，帮助任何人、任何公司更快、更好地研发新医药产品，探索无限可能</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 01 Mar 2021 08:18:08 +0800</pubDate><image><url>http://MzAwMDA5NTIxNQ.favicon.privacyhide.com/favicon.ico</url><title>药明康德 | wechat-feeds</title><link>http://MzAwMDA5NTIxNQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>增强抗PD-1/PD-L1疗法效力，蛋白降解成为新兴策略？</title><link>https://mp.weixin.qq.com/s/sS52PPsFR5z0mclCtOEvrQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQbWYZFFpfUtLx9NHwVaoIA5WSUGLtP7f5zjlgVM0sH4Dl3Nur8vcUAg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>降解PD-1/PD-L1的多种途径]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>速递 | “first-in-class”肽偶联药物获FDA加速批准，治疗多发性骨髓瘤</title><link>https://mp.weixin.qq.com/s/oDbA_C6IKZeR8Z4QuoNG4Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQbSnJEicretz6ZHccVzKOl74dLbWusBibZsGI7vZtibuH1DgnaEKpqqtVA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>强生单剂新冠疫苗获FDA紧急使用授权</title><link>https://mp.weixin.qq.com/s/UKJVGOMYDQM_qi1PyXeAaw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQic5b00Ps9MpfKSGrEqCDy9KykLRe1DiaXebRhSLZicWtZ1t6ZCnAPjP8A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>孤儿药周报 | 百时美施贵宝BMCA抗体偶联药物、康方生物PD-1单克隆抗体等入围</title><link>https://mp.weixin.qq.com/s/IGP8nFMPa_XlPUcjD20Ocg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQXS3mUojhicBib7cczMqE9WicTfNt19EPDicicqrY8SfxM20iaxc1RYibDXE5g/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>艾伯维JAK抑制剂达到3期临床终点；默沙东18.5亿美元拓展自身免疫疾病研发管线</title><link>https://mp.weixin.qq.com/s/zlHHNoRJDI_OFga7drC2Gw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gNgqG1xzIhbHQL4aJ8o6JWib3hXsUx6z3jczUN8OadRne8FKLR1guhUicNGKIsTgSZnibYa3lWeb571A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>行业一周新闻回顾]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>明日下午3点！灵活多样质粒工艺开发平台，推动细胞基因治疗研发进程</title><link>https://mp.weixin.qq.com/s/2QweVMvWFiT7lNyo1dy_Hw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gO1bODoX0ibtQmBicSz7Lj7TQiapTUHI6vpD5lC0usM4b6YZjdEr6Yfy8iblAKN2xd7PL95ibYHicK7BCBA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>基因治疗系列（三）]]></content:encoded><pubDate>Mon, 01 Mar 2021 07:37:08 +0800</pubDate></item><item><title>2020年获批罕见病疗法中有哪些“第一”？| 国际罕见病日</title><link>https://mp.weixin.qq.com/s/14eOTZPr70LUg7TYzPYu2w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVr5urcOJoSzUUOSObiaDaBrFib3y2cCoDWBcIIf6WgYeCRicMrrSdZa2VEA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>罕见病专栏 | 一周罕闻药事（2.16-2.25）</title><link>https://mp.weixin.qq.com/s/k8oKwnD5dTjZoPeDjAOpCg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gNDMeJZiaFaqUv0lLceQMa9ty1gibZQWibPicficre59nB0wZjJib5kdHo18yicQHGq9Se99gJ6KCvafYW2A/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>罕闻药事，为您汇总罕见病研发领域最新资讯]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>速递 | 22：0！强生单剂新冠疫苗获咨询委员会全票支持</title><link>https://mp.weixin.qq.com/s/b_XkFcLwyulCd6WVTAuYWg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVrK7q9TARwdmAmHg0TEYIGaibuib04DPsuJibcg6FCchNoaKP9SiaNFyL8GA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>有望明日获FDA紧急使用授权]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>速递 | 降低疾病加重率56%，潜在“first-in-class”抗体疗法达到所有3期主要终点</title><link>https://mp.weixin.qq.com/s/EHVAoi1Jqkc3q02L1WriTA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVrNHfgWmia6NVe7cSzEMJhRNXoApkP3FICe8Cee4hCZEk4ThdicOwHGsDg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>在广泛重度哮喘患者人群中一致性降低疾病加重率]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>速递 | 治疗致命儿童代谢缺陷，FDA今日批准首款疗法</title><link>https://mp.weixin.qq.com/s/9rMXpx-nA93yozhFttYxnA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gObHx0odUDfFnESbRP1UTVrZvDsfAiaAx4oPCJftlXyU32xKv9uhjWpvuz2ZS6wGU65fHic5ibAkEcGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Sat, 27 Feb 2021 08:06:13 +0800</pubDate></item><item><title>FDA今日加速批准DMD疗法上市，还有这些疗法值得患者期待</title><link>https://mp.weixin.qq.com/s/15P38SGf1BPOD6G2KJzUVg</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMPyY57lJol1L1O0hJbicfMibOgrib0s1fGEL78lfcCpeRYKRa8INrDQgTmlvVSWMoiaCSmyFHbic3IdRw/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>新冠疗法临床试验中只有5%能够给出指导性结果？FDA代理局长联名发文</title><link>https://mp.weixin.qq.com/s/8pgjgrAr0UIQwX7oqcTR8Q</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMPyY57lJol1L1O0hJbicfMibXiaict6IlcU8m1D8058rgEbloiaUeWJDpNeia4XE7icfHZNGahiamIM6TF8Q/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>速递 | 18.5亿美元拓展自身免疫疾病研发管线，默沙东囊获IL-2靶向疗法</title><link>https://mp.weixin.qq.com/s/loZwTFxb0OH2xCEy3tS0LQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gMPyY57lJol1L1O0hJbicfMibZvuwu1jft3PupLguia2rCRvnSfic4lw5EdPC7Y0EG0ibHmpdnAIDGM4YQ/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>特异性激活调节性T细胞]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>减少92%新冠感染和94%病例，NEJM发表以色列60万人接种辉瑞/BioNTech疫苗数据</title><link>https://mp.weixin.qq.com/s/zh9gMHmq9ZbzMdjgQjnh5w</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/EIicaxb3hLFX1qZzOycObO41Na4A1DbYZXN9EHh7goq24DbZrkcU7PtJPA1B9HTuKiaAUpficEr1pjcIyOWntSoFA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>真实保护数据和3期临床试验结果非常接近]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>《麻省理工科技评论》2021全球十大突破技术公布，mRNA疫苗、远程医疗等上榜</title><link>https://mp.weixin.qq.com/s/szvOm11IrKDduKPfDdpGvw</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/UdvecgtVRYK6B6KXYXV9sFsmmjsrH9SEGKFksosABMvHtdEDzsNJr1hSKaKCPCbibgCbTry5yr3d1eRZL6GBSjA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>这几项技术都与新冠疫情密切相关，是危机催生机遇的最好写照。]]></content:encoded><pubDate>Fri, 26 Feb 2021 08:11:53 +0800</pubDate></item><item><title>展现预防无症状感染潜力，FDA公布强生单剂新冠疫苗最新结果</title><link>https://mp.weixin.qq.com/s/Cat6icQ_44AJT6FmX-7IMA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gOh1FkqJTqA5OmIPufVbH495PODxczKL6xIEDGoDMY5NPS71hERUvsBIG3ibDiawNhrC9iagkvOgcVMg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>有望本周获得FDA授予的紧急使用授权]]></content:encoded><pubDate>Thu, 25 Feb 2021 07:46:12 +0800</pubDate></item><item><title>针对新冠突变病毒，Moderna改良疫苗即将开始临床试验</title><link>https://mp.weixin.qq.com/s/dYqyk3nP71OkAO-bIxMEbQ</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gOh1FkqJTqA5OmIPufVbH49owBqYib6c1txaGmF4EaznRkEZ9CV9WQ0f9LrrwlSt1kxDs08B4IZviag/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Thu, 25 Feb 2021 07:46:12 +0800</pubDate></item><item><title>速递 | 康希诺腺病毒载体新冠疫苗附条件上市申请获中国国家药监局受理</title><link>https://mp.weixin.qq.com/s/0XGgxiNR-MekdkfEsTv5hA</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gOh1FkqJTqA5OmIPufVbH49iby97SA5AticXrVpnycNvu0kq5Go1xV478fOB68DjbcPgzla9NfibjDGg/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>药明康德]]></content:encoded><pubDate>Thu, 25 Feb 2021 07:46:12 +0800</pubDate></item><item><title>速递 | 抑制RAS信号传导，创新头颈癌疗法获FDA突破性疗法认定</title><link>https://mp.weixin.qq.com/s/JTCCfwF_S-YX_QucKVvN_A</link><description></description><content:encoded><![CDATA[<img src="http://mmbiz.qpic.cn/mmbiz_jpg/FcLK21Ir4gOh1FkqJTqA5OmIPufVbH49HpqrhicjAJciaUatutOqRgTBrzu8QzrnbGZZO7icZyLbQtW23NI0OyEjA/0?wx_fmt=jpeg" referrerpolicy="no-referrer"><br>客观缓解率达50%]]></content:encoded><pubDate>Thu, 25 Feb 2021 07:46:12 +0800</pubDate></item></channel></rss>